These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35740902)

  • 21. alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis.
    Zhang NY; Tang Z; Liu CW
    J Biol Chem; 2008 Jul; 283(29):20288-98. PubMed ID: 18502751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers.
    Fiolek TJ; Keel KL; Tepe JJ
    ACS Chem Neurosci; 2021 Apr; 12(8):1438-1448. PubMed ID: 33788542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasome activator 28γ (PA28γ) allosterically activates trypsin-like proteolysis by binding to the α-ring of the 20S proteasome.
    Thomas TA; Smith DM
    J Biol Chem; 2022 Aug; 298(8):102140. PubMed ID: 35714770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.
    Njomen E; Tepe JJ
    J Med Chem; 2019 Jul; 62(14):6469-6481. PubMed ID: 30839208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced protein aggregation.
    Dal Vechio FH; Cerqueira F; Augusto O; Lopes R; Demasi M
    Free Radic Biol Med; 2014 Feb; 67():304-13. PubMed ID: 24291399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.
    Coleman RA; Muli CS; Zhao Y; Bhardwaj A; Newhouse TR; Trader DJ
    Bioorg Med Chem Lett; 2019 Feb; 29(3):420-423. PubMed ID: 30587447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calpain-resistant fragment(s) of alpha-synuclein regulates the synuclein-cleaving activity of 20S proteasome.
    Kim HJ; Lee D; Lee CH; Chung KC; Kim J; Paik SR
    Arch Biochem Biophys; 2006 Nov; 455(1):40-7. PubMed ID: 17005155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Disordered Landscape of the 20S Proteasome Substrates Reveals Tight Association with Phase Separated Granules.
    Myers N; Olender T; Savidor A; Levin Y; Reuven N; Shaul Y
    Proteomics; 2018 Nov; 18(21-22):e1800076. PubMed ID: 30039638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
    Thibaudeau TA; Anderson RT; Smith DM
    Nat Commun; 2018 Mar; 9(1):1097. PubMed ID: 29545515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceleration of Protein Degradation by 20S Proteasome-Binding Peptides Generated by In Vitro Artificial Evolution.
    Zhu Y; Shigeyoshi K; Hayakawa Y; Fujiwara S; Kishida M; Ohki H; Horibe T; Shionyu M; Mizukami T; Hasegawa M
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The C-Terminus of the PSMA3 Proteasome Subunit Preferentially Traps Intrinsically Disordered Proteins for Degradation.
    Biran A; Myers N; Steinberger S; Adler J; Riutin M; Broennimann K; Reuven N; Shaul Y
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The nuclear proteasome and the degradation of oxidatively damaged proteins.
    Voss P; Grune T
    Amino Acids; 2007; 32(4):527-34. PubMed ID: 17103119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal mechanistic component of HbYX-dependent proteasome activation that reverses impairment by neurodegenerative-associated oligomers.
    Chuah JJY; Thibaudeau TA; Smith DM
    Commun Biol; 2023 Jul; 6(1):725. PubMed ID: 37452144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines.
    Alvarez-Castelao B; Goethals M; Vandekerckhove J; Castaño JG
    Biochim Biophys Acta; 2014 Feb; 1843(2):352-65. PubMed ID: 24315858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allosteric regulation of the 20S proteasome by the Catalytic Core Regulators (CCRs) family.
    Deshmukh FK; Ben-Nissan G; Olshina MA; Füzesi-Levi MG; Polkinghorn C; Arkind G; Leushkin Y; Fainer I; Fleishman SJ; Tawfik D; Sharon M
    Nat Commun; 2023 May; 14(1):3126. PubMed ID: 37253751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.
    Cao Y; Tu Y; Fu L; Yu Q; Gao L; Zhang M; Zeng L; Zhang C; Shao J; Zhu H; Zhou Y; Li J; Zhang J
    Eur J Med Chem; 2022 Apr; 233():114211. PubMed ID: 35218994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Peptidomimetic Fluorescent Probe to Detect the Trypsin β2 Subunit of the Human 20S Proteasome.
    Wysocka M; Romanowska A; Gruba N; Michalska M; Giełdoń A; Lesner A
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration.
    Opoku-Nsiah KA; Gestwicki JE
    Transl Res; 2018 Aug; 198():48-57. PubMed ID: 30244692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boc
    Shi Y; Long MJ; Rosenberg MM; Li S; Kobjack A; Lessans P; Coffey RT; Hedstrom L
    ACS Chem Biol; 2016 Dec; 11(12):3328-3337. PubMed ID: 27704767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ηigh-resolution structure of mammalian PI31-20S proteasome complex reveals mechanism of proteasome inhibition.
    Hsu HC; Wang J; Kjellgren A; Li H; DeMartino GN
    J Biol Chem; 2023 Jul; 299(7):104862. PubMed ID: 37236357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.